Dear Editor,Malignant pleural effusion(MPE)has been reported in~40%of advanced non-small cell lung cancer(NSCLC)patients,most frequently in those with lung adenocarcinoma(LUAD).Epidermal growth factor receptor tyrosin...Dear Editor,Malignant pleural effusion(MPE)has been reported in~40%of advanced non-small cell lung cancer(NSCLC)patients,most frequently in those with lung adenocarcinoma(LUAD).Epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)have brought a significant improvement in the clinical treatment of advanced EGFR-mutant NSCLC,however,during the early stage of EGFR-TKI administration,progression of MPE rather than lung lesions has been observed in a small group of patients.Although defined as a nontarget lesion by the Response Evaluation Criteria in Solid Tumors(RECIST)guidelines(version 1.1),MPE represents true neoplastic pleural dissemination and worse prognosis.In this situation,some clinicians tend to give up targeted therapy and switch to chemotherapy,since it seems that the patients do not benefit from EGFR-TKI treatment.Therefore,it is necessary to explore the underlying mechanism of early MPE progression for better clinical decision-making.展开更多
基金supported by the National Natural Science Foundation of China(Grant no.81472197 and 81673001).
文摘Dear Editor,Malignant pleural effusion(MPE)has been reported in~40%of advanced non-small cell lung cancer(NSCLC)patients,most frequently in those with lung adenocarcinoma(LUAD).Epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)have brought a significant improvement in the clinical treatment of advanced EGFR-mutant NSCLC,however,during the early stage of EGFR-TKI administration,progression of MPE rather than lung lesions has been observed in a small group of patients.Although defined as a nontarget lesion by the Response Evaluation Criteria in Solid Tumors(RECIST)guidelines(version 1.1),MPE represents true neoplastic pleural dissemination and worse prognosis.In this situation,some clinicians tend to give up targeted therapy and switch to chemotherapy,since it seems that the patients do not benefit from EGFR-TKI treatment.Therefore,it is necessary to explore the underlying mechanism of early MPE progression for better clinical decision-making.
